Medical Education podcast by COR2ED. Professor James Harding, HCC Connect member, provides his perspectives and insights on key abstracts and topics discussed at ASCO GI 2022 and EASL liver cancer summit 2022 in hepatocellular carcinoma. He discusses the HIMALAYA study which evaluated dual immune checkpoint blockade inhibition namely, anti-CTLA-4 antibody tremelimumab with the anti-PD-L1 antibody durvalumab in the frontline setting with patients with unresectable hepatocellular carcinoma. There were other important studies at the meeting and Prof Harding highlights the RENOBATE study and the GOING study that evaluated nivolumab in combination with regorafenib and early addition of nivolumab to regorafenib regimen, respectively.
In this episode, Dr Choo discusses some key abstracts presented during the virtual ASCO and WCGIC congresses in 2021. Dr Choo comments that despite...
What are the common pre-analytical phase challenges in ovarian cancer, and how can we overcome them? Why is it important to identify genetic alterations? ...
¿Cuáles son los desafíos frecuentes en la fase preanalítica del cáncer de ovario, y cómo podemos solucionarlos? ¿Por qué es importante identificar las alteraciones...